Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

RCT (n=552) reports at a median follow-up of 7.5 months, overall response with subcutaneous (SC) administration met predefined non-inferiority criteria: overall response seen in 41% of patients in SC group and 37% of patients in IV group (relative risk 1.11, 95% CI 0.89–1.37).

SPS commentary:

Daratumumab is currently only licensed for intravenous administration.


The Lancet Haematology